New dosing strategy tested for muscle-weakening disease

NCT ID NCT04980495

Completed Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

Summary

This study tested whether giving a medication called efgartigimod continuously or in cycles works better for people with generalized myasthenia gravis, a condition that causes muscle weakness. The trial involved 69 adults who received the medication for up to 138 weeks. Researchers measured how well the different dosing schedules controlled symptoms and improved daily activities.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigator Site 1 - GEO9950001

Tbilisi, 0114, Georgia
Investigator Site 10 - US0010007

Carlsbad, California, 92011, United States
Investigator Site 11 - US0010011

Austin, Texas, 78756, United States
Investigator Site 12 - US0010004

Kansas City, Kansas, 66160, United States
Investigator Site 13 - US0010013

Portland, Oregon, 97239, United States
Investigator Site 14 - US0010010

Richmond, Virginia, 23219, United States
Investigator Site 15 - US0010014

Coral Springs, Florida, 33067, United States
Investigator Site 16 - US0010009

Augusta, Georgia, 30910, United States
Investigator Site 17 - US0010012

Philadelphia, Pennsylvania, 19104, United States
Investigator Site 18 - ES0340002

Santiago de Compostela, A Coruña, 15706, Spain
Investigator Site 19 - ES0340001

Barcelona, 08041, Spain
Investigator Site 2 - GEO9950002

Tbilisi, 0112, Georgia
Investigator Site 20 - FR0330001

Marseille, 13385, France
Investigator Site 21 - IT0390002

Milan, 20133, Italy
Investigator Site 22 - IT0390001

Roma, 00168, Italy
Investigator Site 23 - FR0330005

Bordeaux, 33604, France
Investigator Site 24 - FR0330004

Lille, 59000, France
Investigator Site 25 - FR0330003

Nice, 06001, France
Investigator Site 26 - AT0430002

Innsbruck, 6020, Austria
Investigator Site 27 - AT0430001

Vienna, 1090, Austria
Investigator Site 28 - BE0320001

Leuven, 3000, Belgium
Investigator Site 29 - CA0019003

London, N6A 5A5, Canada
Investigator Site 3 - GEO9950003

Tbilisi, 0114, Georgia
Investigator Site 30 - IT0390004

Genova, 16132, Italy
Investigator Site 31 - IT0390005

Bologna, 40139, Italy
Investigator Site 32 - DE0490001

Essen, 45147, Germany
Investigator Site 33 - DE0490004

Berlin, 10117, Germany
Investigator Site 34 - DE0490005

Hanover, 30625, Germany
Investigator Site 35 - NL0310001

Amsterdam, 1105, Netherlands
Investigator Site 36 - DE0490002

Bochum, 44791, Germany
Investigator Site 4 - PL0480001

Lubin, 20-093, Poland
Investigator Site 5 - PL0480002

Krakow, 31-426, Poland
Investigator Site 6 - US0010008

Meadows, Illinois, 60008, United States
Investigator Site 7 - US0010001

Orange, California, 92868, United States
Investigator Site 8 - US0010003

Chicago, Illinois, 60611, United States
Investigator Site 9 - 0010006

Boca Raton, Florida, 33487, United States
Investigator site 37 - CA0019002

Québec, H3A 2B4, Canada
Investigator site 38 - FR0330002

Paris, 75013, France
Investigator site 39 - IT0390006

Pisa, 56126, Italy

Conditions

Explore the condition pages connected to this study.

GENERALIZED MYASTHENIA GRAVIS GMG MG - MYASTHENIA GRAVIS